Investigators from the SWOG Cancer Research Network have developed and validated a risk prediction model for identifying which patients with advanced cancer who are enrolled to clinical trials are at ...

Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), will share results of ...

Two potentially practice-changing studies published this month in the New England Journal of Medicine showcase the biostatistical expertise at the SWOG Statistics and Data Management Center (SDMC) ...

CHICAGO — June 5, 2017 — For an investment of $125 for each year of life gained since the 1950s, the National Cancer Institute-funded SWOG clinical trials program has added 3.34 million years of life ...

SWOG Clinical Trials Partnerships (SWOG CTP) has signed a collaborative research agreement with Novartis Pharmaceuticals Corporation to form a strategic alliance via our Preferred Partnership Program ...

The Lancet study shows addition of bortezomib significantly improves survival in treatment-naïve patients with multiple myeloma. In treatment-naïve patients with multiple myeloma, including ...

Pivotal Phase 3 trial of MO-03 builds on prior studies that demonstrated enhanced immunotherapy benefit without added toxicity MOUNTAIN VIEW, Calif., January 08, 2026--(BUSINESS WIRE)--Osel Inc., a ...

SWOG Cancer Research Network and its charity, The Hope Foundation for Cancer Research, announce the award of two grants designed to give military veterans better access to cancer clinical trials.

A phase II trial of LEE011 in combination with everolimus in the treatment of advanced well differentiated neuroendocrine tumors of foregut origin. Background: Clinical outcomes after curative therapy ...

SAN FRANCISCO, May 31, 2023 /PRNewswire/ -- The SWOG-nCartes EHR-to-EDC collaboration between nCoup and the SWOG Cancer Research Network was showcased at the Spring 2023 SWOG Hybrid Group Meeting ...

Patient-reported outcomes may be associated with cancer outcomes. We evaluated clinically significant fatigue (CSF), overall survival, adverse events (AEs), and quality of life (QOL) during cancer ...